Program 3. Discovery and Developmental Therapeutics (DDT): The overall scientific goal of the Cancer Discovery and Developmental Therapeutics (DDT) Program is to enhance the discovery of new agents and advance their translation into the prevention and treatment of patients with cancer. The program has two full specific aims, and two major developing aims. The overall goal is to foster a highly collaborative team science environment, building on the existing strong ties with the MPB, CGE and CCPS Programs, to promote molecular target-based cancer drug discovery and to facilitate translational clinical trials for effective therapeutic development. To achieve this goal, the Program is organized with the following foci: (1) To identify small molecule modulators of tumor-addicted signaling pathways for cancer drug discovery;(2) To carry out mechanism-driven clinical trials for cancer drug development to rapidly move new agents to patients;(3) To translate discoveries in cancer immunology into mechanistically driven clinical trials enhancing the therapy of patients with hematologic malignancies and immuno-responsive solid tumors;(4) To test promising agents early in their life cycle in the multi-modality setting using mechanism-based clinical trials in conjunction with optimized chemo-radiation, radiation or surgery. We plan to achieve the goal of developing novel therapeutic approaches to the prevention and treatment of cancer through close intra- and inter-programmatic interactions by focusing on such areas as: (1) chemoprevention, (2) molecularly-targeted therapy, (3) new drug discovery, (4) biological interaction between epithelial and surrounding tissue, (5) nanotherapeutics, (6) cancer immunotherapy, (7) biomedical research platforms using innovative technology to prevent and treat tumors, and (8) translational multimodality research for advanced solid malignancies. The DDT Program comprises a diverse group of 45 members from 15 different departments within the School of Medicine, the School of Public Health and Emory College. The DDT Program has total peerreviewed program funding of $23 M, of which NCI funding represents $17.5M ($13.6M direct). In addition, there is a total of $1.9 M in non-peer-reviewed support from various sources. Program members have published a total of 535 papers during the last five years, of which 47% are intra-programmatic and 53% are inter-programmatic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138292-03
Application #
8249480
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2012-07-31
Budget Start
2011-04-01
Budget End
2012-07-31
Support Year
3
Fiscal Year
2011
Total Cost
$76,082
Indirect Cost
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Danish, Hasan; Ferris, Matthew J; Balagamwala, Ehsan et al. (2018) Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma. Melanoma Res 28:120-125
Barwick, Benjamin G; Scharer, Christopher D; Martinez, Ryan J et al. (2018) B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation. Nat Commun 9:1900
Liu, Fakeng; Liu, Yuan; Liu, Xiuju et al. (2018) Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Lung Cancer 123:36-43
Kennedy, E M; Powell, D R; Li, Z et al. (2018) Galactic Cosmic Radiation Induces Persistent Epigenome Alterations Relevant to Human Lung Cancer. Sci Rep 8:6709
Cassidy, Richard J; Zhang, Xinyan; Switchenko, Jeffrey M et al. (2018) Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer 124:775-784
Xiao, Canhua; Beitler, Jonathan J; Higgins, Kristin A et al. (2018) Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer. Brain Behav Immun 74:291-295
Jhaveri, Jaymin; Rayfield, Lael; Liu, Yuan et al. (2018) Impact of intensity modulated radiation therapy on survival in anal cancer. J Gastrointest Oncol 9:618-630
Jhaveri, Jaymin; Chowdhary, Mudit; Zhang, Xinyan et al. (2018) Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases. J Neurosurg :1-7
Chowdhary, Mudit; Switchenko, Jeffrey M; Press, Robert H et al. (2018) Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol 139:689-697
Bilen, Mehmet Asim; Dutcher, Giselle Marie Almeida; Liu, Yuan et al. (2018) Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin Genitourin Cancer 16:e563-e575

Showing the most recent 10 out of 331 publications